TerminatedPhase 2NCT01855724
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hellenic Cooperative Oncology Group
- Principal Investigator
- Joseph Sgouros, MD3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital
- Intervention
- Gemcitabine-Pazopanib(drug)
- Enrollment
- 29 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2018
Study locations (17)
- 2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital, Athens, Greece
- Dept of Medical Oncology, 251 General Air Force Hospital, Athens, Greece
- 2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio", Athens, Greece
- Oncology Dept, 2nd Surgyc Clinic, Aretaieio Hospital, Athens, Greece
- Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra", Athens, Greece
- Division of Oncology, 2nd Dept of Internal Medicine, Propaedeutic, University Hospital "Attikon", Athens, Greece
- 2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
- 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
- 3rd Dept of Medical Oncology, Hygeia Hospital, Athens, Greece
- 1st Dept of Medical Oncology, Metropolitan Hospital, Athens, Greece
- 2nd Dept of Medical Oncology, Metropolitan Hospital, Athens, Greece
- Dept of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece
- Dept of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
- Division of Oncology, Dept of Internal Medicine, University Hospital of Patras, Pátrai, Greece
- 2nd Dept of Medical Oncology, EUROMEDICA General Clinic of Thessaloniki, Thessaloniki, Greece
- +2 more locations on ClinicalTrials.gov
Collaborators
GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01855724 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNCT07206355In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersUniversity of Nottingham